In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Transgene raises $52.7mm through rights offering

Executive Summary

Transgene (gene therapy) netted $52.7mm (Euro61.4mm) through a rights offering of 4.2mm ordinary shares at $13.21 each. In April the company was looking for $72mm (Euro79.5mm) for up to 5.3mm ordinary shares at $13.56 (Euro15) apiece (or 15.9mm American Depository Shares with one ordinary share equaling three ADSs).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies